Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies
characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly …

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level.
Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to …

Childhood B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by recurrent
genetic abnormalities that drive risk-directed treatment strategies. Using current techniques …

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk
factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize …

Acute lymphoblastic leukemia (ALL) is a malignancy that can be subdivided into distinct
entities based on clinical, immunophenotypic and genomic features, including mutations …

Recent genomic studies have provided a refined genetic map of acute lymphoblastic
leukemia (ALL) and increased the number of potential prognostic markers. Therefore, we …

Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic
subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date …

The EBF1-PDGFRB gene fusion accounts for< 1% of B-cell precursor acute lymphoblastic
leukemia (ALL) cases and occurs within the Philadelphia-like ALL subtype. We report 15 …

The t (9; 22)(q34; q11) or Philadelphia chromosome creates a BCR–ABL1 fusion gene
encoding for a chimeric BCR–ABL1 protein. It is present in 3–4% of pediatric acute …

B-lymphocyte development in the bone marrow is controlled by the coordinated action of
transcription factors creating regulatory networks ensuring activation of the B-lymphoid …